The Mundipharma Network of independent associated companies in Europe, recognise the threat to global health posed by diabetes and is therefore proud to offer innovative medicines targeted at treating patients with type 2 diabetes.
Type 2 diabetes accounts for 90% 1 of diabetes patients and is a long-term disorder that is characterised by high blood sugar, insulin resistance, and a relative lack of insulin.
Mundipharma has a strong heritage across Europe in specialist driven primary care and, through our work in Diabetes, we further strengthen our commitment to making available innovative medicines that add real value to patients and healthcare systems.
Please note that the medicines mentioned may not be available in all countries. Additionally, currently approved indications and presentations may differ between countries. Please always ask a healthcare professional for advice regarding medicines and refer to individual countries for full product indication and local prescribing information.
INVOKANA® (Canagliflozin) – A sodium-glucose transport protein 2 (SGLT2) inhibitor, is a once daily tablet for type 2 diabetes that helps to lower blood glucose levels by inhibiting its reabsorption in the kidney.
VOKANAMET® (canagliflozin and immediate release metformin hydrochloride fixed dose combination) – A fixed dose combination tablet targeted at improving glycaemic control of adult patients with type 2 diabetes.
Press return to search